Amgen has invested $66m in genetic sequencing system provider Oxford Nanopore, increasing its latest funding round to $206m.
Oxford Nanopore Technologies, a UK-based sequencing technology spinout of University of Oxford, raised £50m ($66m) from pharmaceutical firm Amgen today to expand its latest funding round to $206m.
The company had secured an initial $140m in March this year from GIC, the sovereign wealth fund of Singapore, Australian superannuation fund Hostplus, financial services firm China Construction Bank and unnamed existing investors.
Founded in 2005, Oxford Nanopore has created real-time, low-cost DNA and RNA sequencing technology that has applications in…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
